WASHINGTON, Nov. 25 (Xinhua) -- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced on Wednesday that the fourth iteration of the Adaptive COVID-19 Treatment Trial (ACTT-4) has begun to enroll hospitalized COVID-19 adults who require supplemental oxygen.
The NIAID-sponsored trial will enroll up to 1,500 patients at approximately 100 sites in the United States and other countries.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!